Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin plus chloroquine vs sulfadoxine plus pyrimethamine for intermittent preventive treatment of falciparum malaria in pregnancy
2014-004952-80Phase 3
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azithromycin, chloroquine, sulfadoxine and pyrimethamine in Falciparum malaria (PF) and malaria (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of subjects with sub-optimal pregnancy outcome (ITT population) and Proportion of subjects with low birth weight live neonates.
02
Drugs
azithromycinchloroquinesulfadoxinepyrimethamine
03
Conditions
Falciparum malaria (PF)malaria
Beyond the preview
Go deeper on 2014-004952-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004952-80.